Ebrotidine

Summary

Ebrotidine (CHEMBL1742471) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 477.4 Da · C14H17BrN6O2S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742471
Name	Ebrotidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65869
Molecular formula	C14H17BrN6O2S3
Molecular weight	477.4
InChIKey	ZQHFZHPUZXNPMF-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br

IUPAC name: N-(4-bromophenyl)sulfonyl-N’-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide

Also known as: Ebrotidina, Ebrotidine, ebrotidine, EBROTIDINE

Patent coverage: 616 distinct patent families (2,441 SureChEMBL compound mentions), from 6 matched compound structure(s). One matched structure accounts for 2,417 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).